Deciphera Pharmaceuticals (DCPH) stock forecast for 2026. Forecast tables and graphs.







Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading

Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …

Deciphera Pharmaceuticals (DCPH) stock forecast for 2026

Updated: April 8, 2024 (06:40)

Sector: Healthcare

The share price of Deciphera Pharmaceuticals, Inc. (DCPH) now

What analysts predict: $24.2
52-week High/Low: $17.73 / $9.9

50/200 Day Moving Average: $15.54 / $14.02

This figure corresponds to the Average Price over the previous 50/200 days. For Deciphera Pharmaceuticals stocks, the 50-day moving average is the resistance level today.

For Deciphera Pharmaceuticals stocks, the 200-day moving average is the resistance level today.

Are you interested in Deciphera Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Deciphera Pharmaceuticals stock price in 2026. How much will one Deciphera Pharmaceuticals share be worth in 2026? Is it worth taking profit / loss on DCPH stock now or waiting? What are analysts' forecasts for Deciphera Pharmaceuticals stock?

We forecast Deciphera Pharmaceuticals stock performance using neural networks based on historical data on DCPH stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.

Deciphera Pharmaceuticals, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Deciphera Pharmaceuticals analysts is $24.2. Today 200 Day Moving Average is the support level (14.02 $). 50 Day Moving Average is the resistance level (15.54 $).




Historical and forecast chart of Deciphera Pharmaceuticals, Inc. stock

The chart below shows the historical price of Deciphera Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the DCPH stock price can be found in the table below.


Deciphera Pharmaceuticals, Inc. is a clinical research biopharmaceutical company.

The company develops drugs designed to improve the lives of cancer patients. Her drug candidates include DCC-2618, DCC-3014 and (Rebastinib) Rebastinib. The platform of kinase switching inhibitors developed by the Company suppresses the process of kinase activation. DCC-2618 is an orally administered inhibitor of kinase switching control for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas including glioblastoma multiforme (GBM), and other solid tumors caused by the pan-KIT or PDGFR gene alpha. DCC-3014 is an orally administered potent and highly selective colony stimulating factor receptor 1 (CSF1R) inhibitor. Rebastinib is a potent and selective oral immunokinase inhibitor of TIE2. Rebastinib binds tightly to the binding region (pocket) of the TIE2 switch, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Deciphera Pharmaceuticals (DCPH) Forecast for 2026

Month Target Pes. Opt. Vol., %
Jan 16.14 14.75 17.17 14.10 %
Feb 16.53 14.31 19.04 24.83 %
Mar 17.85 15.17 18.78 19.20 %
Apr 20.21 17.58 22.79 22.87 %
May 19.88 16.70 23.07 27.59 %
Jun 18.01 16.43 20.00 17.84 %
Jul 19.13 16.64 21.43 22.32 %
Aug 15.88 14.42 17.05 15.46 %
Sep 16.96 15.94 19.16 16.81 %
Oct 18.25 17.19 19.23 10.63 %
Nov 15.40 13.43 16.48 18.50 %
Dec 18.17 16.79 18.94 11.32 %

Deciphera Pharmaceuticals information and performance

Deciphera Pharmaceuticals Address

200 SMITH STREET, WALTHAM, MA, US

Market Capitalization: 1 239 474 000 $

Market capitalization of the Deciphera Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of DCPH shares in the company outstanding by the market price of one share.

EBITDA: -208 858 000 $

EBITDA of Deciphera Pharmaceuticals is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: None

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -2.29

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.329
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 5.89

Enterprise Value (EV) /Revenue

EV To EBITDA: -4.604

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 80800000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Deciphera Pharmaceuticals price target for 2026 by month


Target values for the price of one Deciphera Pharmaceuticals share for Jan 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Jan 2026 is: 16.14.
In Jan, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 14.098% volatility is expected.
Pessimistic target level: 14.75
Optimistic target level: 17.17

Target values for the price of one Deciphera Pharmaceuticals share for Feb 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Feb 2026 is: 16.53.
In Feb, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 24.826% volatility is expected.
Pessimistic target level: 14.31
Optimistic target level: 19.04

Target values for the price of one Deciphera Pharmaceuticals share for Mar 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Mar 2026 is: 17.85.
In Mar, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 19.202% volatility is expected.
Pessimistic target level: 15.17
Optimistic target level: 18.78

Target values for the price of one Deciphera Pharmaceuticals share for Apr 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Apr 2026 is: 20.21.
In Apr, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 22.872% volatility is expected.
Pessimistic target level: 17.58
Optimistic target level: 22.79

Target values for the price of one Deciphera Pharmaceuticals share for May 2026.

The weighted average target price per Deciphera Pharmaceuticals share in May 2026 is: 19.88.
In May, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 27.586% volatility is expected.
Pessimistic target level: 16.70
Optimistic target level: 23.07

Target values for the price of one Deciphera Pharmaceuticals share for Jun 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Jun 2026 is: 18.01.
In Jun, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 17.838% volatility is expected.
Pessimistic target level: 16.43
Optimistic target level: 20.00

Target values for the price of one Deciphera Pharmaceuticals share for Jul 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Jul 2026 is: 19.13.
In Jul, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 22.321% volatility is expected.
Pessimistic target level: 16.64
Optimistic target level: 21.43

Target values for the price of one Deciphera Pharmaceuticals share for Aug 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Aug 2026 is: 15.88.
In Aug, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 15.456% volatility is expected.
Pessimistic target level: 14.42
Optimistic target level: 17.05

Target values for the price of one Deciphera Pharmaceuticals share for Sep 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Sep 2026 is: 16.96.
In Sep, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 16.814% volatility is expected.
Pessimistic target level: 15.94
Optimistic target level: 19.16

Target values for the price of one Deciphera Pharmaceuticals share for Oct 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Oct 2026 is: 18.25.
In Oct, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 10.626% volatility is expected.
Pessimistic target level: 17.19
Optimistic target level: 19.23

Target values for the price of one Deciphera Pharmaceuticals share for Nov 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Nov 2026 is: 15.40.
In Nov, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 18.505% volatility is expected.
Pessimistic target level: 13.43
Optimistic target level: 16.48

Target values for the price of one Deciphera Pharmaceuticals share for Dec 2026.

The weighted average target price per Deciphera Pharmaceuticals share in Dec 2026 is: 18.17.
In Dec, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 11.324% volatility is expected.
Pessimistic target level: 16.79
Optimistic target level: 18.94



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.